Trimebutine 3-thiocarbamoylbenzenesulfonate

Drug Profile

Trimebutine 3-thiocarbamoylbenzenesulfonate

Alternative Names: GIC-1001; TB-905-02

Latest Information Update: 17 Feb 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Antibe Therapeutics
  • Developer gIcare Pharma
  • Class Antispasmodics; Benzenesulfonates; Benzoic acids; Irritable bowel syndrome therapies; Opioid analgesics; Organic sulfur compounds; Phenylbutyrates
  • Mechanism of Action Muscarinic receptor antagonists; Neurotransmitter modulators; Opioid kappa receptor agonists; Opioid mu receptor agonists; Oxygen radical scavengers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Irritable bowel syndrome; Procedural pain

Most Recent Events

  • 17 Feb 2016 No recent reports on development identified - Phase-II for Procedural pain in USA and Canada (PO)
  • 17 Feb 2016 No recent reports on development identified - Preclinical for Irritable bowel syndrome in Canada (PO)
  • 01 Dec 2014 gIcare Pharma completes a phase Ib trial in healthy volunteers in Canada (NCT02276768)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top